Clinical Edge Journal Scan

Node-positive breast cancer: Internal mammary node irradiation may benefit patients with mediocentrally located tumors


 

Key clinical point: Including internal mammary node irradiation (IMNI) with regional node irradiation did not improve disease-free survival (DFS) significantly in the overall cohort of patients with node-positive breast cancer but benefited those with mediocentrally located tumors.

Major finding: The 7-year DFS rate was not significantly different between groups treated without vs with IMNI (81.9% vs 85.3%; hazard ratio [HR], 0.80; 95% CI, 0.57-1.14); however, it was significantly higher in patients with mediocentrally located tumor who were treated with vs without IMNI (91.8% vs 81.6%; HR, 0.42; 95% CI, 0.22-0.82).

Study details: Findings are from phase 3 KROG 08-06 study including 735 patients with histologically confirmed, node-positive breast cancer who underwent breast-conservation surgery or mastectomy and axillary dissection and were randomly assigned to receive regional nodal irradiation with or without IMNI.

Disclosures: This work was supported by the Cancer Control of the Ministry of Health, Welfare, and Family Affairs, Korea. The authors declared no conflict of interests.

Source: Kim YB et al. JAMA Oncol. 2021 Oct 25. doi: 10.1001/jamaoncol.2021.6036 .

Recommended Reading

Breast cancer-related musculoskeletal pain alleviated with acupuncture
MDedge Hematology and Oncology
Cancer risk tied to some manufactured foods
MDedge Hematology and Oncology
Cardiovascular effects of breast cancer treatment vary based on weight, menopausal status
MDedge Hematology and Oncology
Postmenopausal women with early breast cancer can go chemo-free
MDedge Hematology and Oncology
Chemoendocrine therapy beneficial in premenopausal women with node+ breast cancer and low recurrence score
MDedge Hematology and Oncology
Long-term ovarian suppression with GnRHa safe in premenopausal early breast cancer
MDedge Hematology and Oncology
HER2-negative breast cancer: Adding dalpiciclib to fulvestrant prolongs PFS in phase 3
MDedge Hematology and Oncology
HER2-negative advanced breast cancer: LY2780301 + paclitaxel combo shows promise in phase 1b/2
MDedge Hematology and Oncology
Intense dose-dense epirubicin, paclitaxel, cyclophosphamide improves survival in HR+/HER2- BC
MDedge Hematology and Oncology
Impact of COVID-19 pandemic on breast cancer stage at diagnosis and management strategies
MDedge Hematology and Oncology